Extendicare Inc (EXE.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Extendicare Inc (EXE.TO)

32.85

-0.29 (0.88%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

172 watching

Investor Insights

Jun 7, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Extendicare Inc (EXE-T) is attracting attention for its positioning within the growing healthcare sector, particularly as it prepares to cater to an aging population in Ontario. Experts appreciate its strong chart performance and effective margin management, suggesting the company is ready to benefit from increased government funding for home healthcare providers. However, caution is advised due to the market's current exuberance and the presence of well-capitalized private equity competitors. Some analysts express concerns about the stock's current valuation, believing that much of the potential growth may already be reflected in its price. Overall, while the demographic tailwinds are favorable, there is a discernible hesitation regarding its growth prospects relative to peer companies.

Consensus

Cautious

Valuation

Fair Value

Similar

CSH.UN

BUY

A major nursing home operator in North America. 80% of the earnings come from the US. Converting to in income trust which could result in a $28/29 price. Have one of the best franchises in the business. Occupancy rates are very good. Margins are high.

SELL

It looks like the company was put up for auction, but nobody is stopping up to buy it. Would look elsewhere are if you're interested in the healthcare sector.

DON'T BUY

They are doing a strategic review which basically means selling the company. If you own the stock, sell half of it keep half and see what happens. Don't buy.

DON'T BUY

Worries about this industry because of government intervention. Nothing wrong with the fundamental model, but we live in a place where seniors have a lot of political sway and worried about government getting into this industry.

BUY

A first rate company. Looking at it 2/3 years, the demographics are right. They have executed their business plan very well. Good long-term hold.

BUY

The demographics for longer-term care are really good.

WEAK BUY

Might still have some upside. Up 440% in last year.

DON'T BUY

Analysts' expectations are for slightly higher highs. Have been selling some of their Florida assets. Fully priced.

TOP PICK

Has been very solid through the weakness in the market over the last few weeks. Revenue is growing by about 20%. Making acquisitions. Demographics are good.

DON'T BUY

The most obvious way to play the retirement home industry in Canada. Maybe a little further upside, but the easy money has been made.

BUY

Has had a phenomenal recovery. Has been overbought for about four months. Ruled out through a 2001 high. There should be no problem unless you see a loss in momentum. If it dropped below $12.75, it will go down to $8.

BUY ON WEAKNESS

Has had a very good year. Wait for a pullback.

BUY

Have good legs under it.

HOLD

Results have come out better than expected. Should still have some legs. Analysts have a target of $17.

BUY

Has gotten through the worst times. Funding is going to be there from the government. Thinks it can go a lot higher.

Showing 196 to 210 of 237 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Extendicare Inc (EXE.TO)